Abstract 1084
Background
Immune checkpoint inhibitors (ICI) have been demonstrated to improve overall survival (OS) in several cancer types. Atypical patterns of response have been reported including durable responses, pseudoprogression and hyperprogression. We evaluated the occurrence of dissociated response (DR) on immunotherapy.
Methods
We retrieved all patients treated at the Curie Institute with an ICI either alone or in combination with another ICI in the frame of a clinical trial. Patients had to have a baseline CT-scan and at least one follow-up CT-scan, and at least two target lesions (TLs). There was no selection on tumor type. All TLs on CT-scans were assessed by two independent readers according to RECIST 1.1. Three types of DR were evaluated: 1) one TL in partial or complete response (CR/PR) and one progressive TL (DR1), 2) one stable TL and one progressive TL (DR2), and 3) one TL in CR/PR and one stable TL (DR3). Finally, we evaluated the impact of previous radiotherapy and biopsy on TLs on the occurrence of DRs.
Results
1,246 measures of 272 TLs were performed in the 100 patients who met our inclusion criteria. The median number of TLs per patient was 3 [range: 2-5]. 49 out of the 272 TLs (18%) had received prior radiotherapy, and 38 (14%) had been biopsied. Median progression-free survival (PFS) was 3.8 months. Median OS was 13.4 months. Best overall response per patient was a PR/CR in 22%, stable disease (SD) in 33% and progressive disease (PD) in 45%. Best overall response on 272 TLs was a PR/CR in 52 TLs (19%), SD in 142 TLs (52%) and PD in 78 TLs (29%). DR1 were observed in 8% of patients, whereas DR2 and DR3 were observed in 44% and 10% of patients, respectively. While prior irradiation on TLs did not correlate with the occurrence of DRs, DRs were more common when one TL was biopsied ORa = 2.22 (1.28, 3.86) (p = 0.004).
Conclusions
DR with a responding TL and a progressive TL according to RECIST1.1 was observed in 8% of patients. While prior irradiation on TLs did not correlate with the occurrence of DRs, DRs were more common when one TL was biopsied.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Loirat: Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Novartis; Honoraria (institution), Travel / Accommodation / Expenses: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy: Pfizer. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: BMS; Advisory / Consultancy: Amgen; Advisory / Consultancy: Merck; Advisory / Consultancy: Serono; Advisory / Consultancy: Roche; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Nanobiotix; Advisory / Consultancy: GSK. All other authors have declared no conflicts of interest.
Resources from the same session
4614 - Predictors of Response to Checkpoint Inhibitors in Naïve and Ipilimumab-Refractory Melanoma
Presenter: Domenico Mallardo
Session: Poster Display session 3
Resources:
Abstract
2901 - IFN-γ/IL-10 ratio as predictive biomarker for response to anti-PD-1 therapy in metastatic melanoma patients
Presenter: Emilio Giunta
Session: Poster Display session 3
Resources:
Abstract
2306 - Multiplex Chromogenic Immunohistochemistry (IHC) for Spatial Analysis of Checkpoint-Positive Tumor Infiltrating Lymphocytes (TILs)
Presenter: Scott Ely
Session: Poster Display session 3
Resources:
Abstract
1678 - The role of PD-L1 expression as a predictive biomarker in advanced renal cell carcinoma: a meta-analysis of randomized clinical trials.
Presenter: Alberto Carretero-Gonzalez
Session: Poster Display session 3
Resources:
Abstract
5138 - Radiomic Features as a Non-invasive Biomarker to Predict Response to Immunotherapy in Recurrent or Metastatic Urothelial Carcinoma
Presenter: Kye Jin Park
Session: Poster Display session 3
Resources:
Abstract
5800 - Integrative combination of high-plex digital profiling techniques and cluster analysis to reveal complex immune biology in the tumor microenvironment of mesothelioma
Presenter: Carmen Ballesteros-Merino
Session: Poster Display session 3
Resources:
Abstract
5736 - Predictive factors of response to immunotherapy in 198 patients with metastatic non-microcytic lung cancer (mNSCLC): real world data from 2 university hospitals in Spain
Presenter: Juan Felipe Cordoba Ortega
Session: Poster Display session 3
Resources:
Abstract
5645 - Evaluating Lung CT Density Changes Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Treated with Thoracic Radiotherapy (TRT) alone or TRT Followed by Combined Ipilimumab (IPI) and Nivolumab (NIVO).
Presenter: Kujtim Latifi
Session: Poster Display session 3
Resources:
Abstract
1540 - Immuno-oncology therapy biomarkers differences between polyoma-virus positive and negative Merkel cell carcinomas
Presenter: Zoran Gatalica
Session: Poster Display session 3
Resources:
Abstract
4538 - Can we improve patient selection for phase 1 clinical trials (Ph1) based on Immuno-Oncology score prognostic index (VIO)?
Presenter: Ignacio Matos Garcia
Session: Poster Display session 3
Resources:
Abstract